They are designed to selectively recognize and target tumor antigens.849 Enfortumab vedotin, an anti-Nectin-4 monoclonal antibody conjugated with monomethyl auristatin E (MMAE), serves as a prime example of targeted therapy against solid tumors with elevated Nectin-4 expression. Here, NECTIN4 is linked to neoplasm.